Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Alethia, International Biotech Center (IBC) Generium deal

Alethia and IBC Generium partnered to co-develop Alethia's AB-16B5, an IgG2 mAb against

Read the full 133 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE